EP0062

EP0062 is a small-molecule drug developed by Ellipses Pharma. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT05573126, plans to enrol 95 participants with primary completion expected 2028-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.